{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:28:27Z","timestamp":1785479307012,"version":"3.56.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":72,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1053\/j.seminhematol.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:12:04Z","timestamp":1776237124000},"page":"28-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["More disease-modifying therapies for sickle cell disease: Are small molecules and drug repurposing the way forward?"],"prefix":"10.1053","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-2175","authenticated-orcid":false,"given":"Charles T.","family":"Quinn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminhematol.2026.04.001_bib0001","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Prim"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.04.001_bib0002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ajh.21952","article-title":"Reconstructing sickle cell disease: a data-based analysis of the \u201chyperhemolysis paradigm\u201d for pulmonary hypertension from the perspective of evidence-based medicine","volume":"86","author":"Hebbel","year":"2011","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.04.001_bib0003","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMct0708272","article-title":"Hydroxyurea for the treatment of sickle cell anemia","volume":"358","author":"Platt","year":"2008","journal-title":"New Engl J Medicine"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.04.001_bib0004","first-page":"1061","article-title":"The modern use of hydroxyurea for children with sickle cell anemia","volume":"110","author":"Quinn","year":"2025","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.04.001_bib0005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.04.001_bib0006","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of Pain crises in Sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"New Engl J Medicine"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.04.001_bib0007","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1053\/j.seminhematol.2026.04.001_bib0008","unstructured":"Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA\u00ae (voxelotor) From Worldwide Markets. Accessed November 11, 2024. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.04.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31475","article-title":"The Voxelotor effect: decreased affinity for new drugs for sickle cell disease?","volume":"72","author":"Quinn","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"14","key":"10.1053\/j.seminhematol.2026.04.001_bib0011","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJM198404053101401","article-title":"Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea","volume":"310","author":"Letvin","year":"1984","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.04.001_bib0012","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1172\/JCI111464","article-title":"Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia","volume":"74","author":"Platt","year":"1984","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.04.001_bib0013","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/bjh.17663","article-title":"Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia","volume":"194","author":"Quinn","year":"2021","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1053\/j.seminhematol.2026.04.001_bib0014","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1182\/blood.V124.21.4073.4073","article-title":"Are there true non-responders to hydroxyurea in Sickle cell disease? A multiparameter analysis","volume":"124","author":"Chand","year":"2014","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.04.001_bib0015","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/bloodadvances.2020001701","article-title":"Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study","volume":"4","author":"Hodges","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.04.001_bib0016","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/cpt.2028","article-title":"Changing the clinical paradigm of hydroxyurea treatment for sickle cell anemia through precision medicine","volume":"109","author":"Dong","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.04.001_bib0017","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1182\/blood-2018-03-818161","article-title":"How I treat the older adult with sickle cell disease","volume":"132","author":"Thein","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.04.001_bib0018","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V42.6.835.835","article-title":"The role of red cell energy metabolism in the generation of irreversibly sickled cells in vitro","volume":"42","author":"Jensen","year":"1973","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.04.001_bib0019","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2141.2003.04781.x","article-title":"Reactive oxygen species and phosphatidylserine externalization in murine sickle red cells","volume":"124","author":"Banerjee","year":"2004","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1053\/j.seminhematol.2026.04.001_bib0020","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1182\/blood.2020008635","article-title":"Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy","volume":"137","author":"Rab","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.04.001_bib0021","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1172\/JCI106294","article-title":"Effect of 2,3-diphosphoglycerate on oxygen affinity of blood in sickle cell anemia","volume":"49","author":"Charache","year":"1970","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.04.001_bib0022","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3324\/haematol.2019.238865","article-title":"AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes","volume":"106","author":"Rab","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.04.001_bib0023","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1046\/j.1365-2141.1998.01094.x","article-title":"A new sickle cell disease phenotype associating Hb S trait, severe pyruvate kinase deficiency (PK Conakry), and an \u03b12 globin gene variant (Hb Conakry)","volume":"103","author":"Cohen-Solal","year":"1998","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.04.001_bib0024","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1179\/102453308X343536","article-title":"Sickle cell disease in a carrier with pyruvate kinase deficiency","volume":"13","author":"Alli","year":"2008","journal-title":"Hematology"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.04.001_bib0025","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1182\/blood.2022015403","article-title":"A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease","volume":"140","author":"Xu","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.04.001_bib0026","first-page":"E226","article-title":"Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: a phase 2, open-label study","volume":"97","author":"van","year":"2022","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1053\/j.seminhematol.2026.04.001_bib0027","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1182\/bloodadvances.2023011477","article-title":"One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study","volume":"7","author":"van","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.04.001_bib0028","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(24)00319-3","article-title":"Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial","volume":"12","author":"Idowu","year":"2025","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.04.001_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.brci.2025.100014","article-title":"Long-term mitapivat treatment is safe and efficacious in patients with sickle cell disease","volume":"1","author":"Conrey","year":"2025","journal-title":"Blood Red Cells Iron"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.04.001_bib0031","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/cpdd.1058","article-title":"Safety, pharmacokinetics, and pharmacodynamics of Etavopivat (FT-4202), an allosteric activator of pyruvate kinase-R, in healthy adults: a randomized, placebo-controlled, double-blind, first-in-Human phase 1 trial","volume":"11","author":"Forsyth","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.04.001_bib0032","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1124\/jpet.121.000743","article-title":"Etavopivat, a pyruvate kinase activator in red blood cells, for the treatment of sickle cell disease","volume":"380","author":"Schroeder","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.04.001_bib0033","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1182\/bloodadvances.2023012467","article-title":"Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease","volume":"8","author":"Saraf","year":"2024","journal-title":"Blood Adv"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.04.001_bib0034","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood.2022016930","article-title":"RBC, heal thyself: PK activators in SCD","volume":"140","author":"Little","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.04.001_bib0035","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00000441-197210000-00004","article-title":"The effect of oral urea administration on red cell survival in sickle cell disease","volume":"264","author":"BENSINGER","year":"1972","journal-title":"Am J M\u00e9d Sci"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.04.001_bib0036","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1073\/pnas.68.11.2791","article-title":"Increased survival of sickle-cell erythrocytes after treatment in vitro with sodium cyanate","volume":"68","author":"Gillette","year":"1971","journal-title":"Proc National Acad Sci"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.04.001_bib0037","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1172\/JCI107516","article-title":"Life span of carbamylated red cells in sickle cell anemia","volume":"52","author":"Milner","year":"1973","journal-title":"J Clin Invest"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.04.001_bib0038","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood.2021012070","article-title":"Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin","volume":"138","author":"Henry","year":"2021","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminhematol.2026.04.001_bib0039","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1056\/NEJMra2212266","article-title":"Oxygen delivery in the treatment of anemia","volume":"387","author":"Bunn","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2026.04.001_bib0040","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29805","article-title":"New therapeutics for children with sickle cell disease: a time for celebration, caution, or both?","author":"Quinn","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.04.001_bib0041","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1111\/bjh.19697","article-title":"Therapeutic potential of the latest oxygen affinity-modifying agent, GBT021601, for treating sickle cell disease is questionable","volume":"205","author":"Alaimo","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2026.04.001_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106161","article-title":"Accelerated approval of Oxbryta\u00ae (voxelotor): a case study on novel endpoint selection in sickle cell disease","volume":"98","author":"Lehrer-Graiwer","year":"2020","journal-title":"Contemp Clin Trials"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.04.001_bib0043","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29716","article-title":"Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years","volume":"69","author":"Estepp","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminhematol.2026.04.001_bib0044","unstructured":"Notification to the CHMP\/EMA Secretariat of a referral under article 20 of regulation (EC) 726\/2004. Accessed November 11, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/oxbryta-article-20-procedure-notification_en.pdf."},{"key":"10.1053\/j.seminhematol.2026.04.001_bib0045","unstructured":"EMA starts review of sickle cell disease medicine Oxbryta: review follows reports of fatal cases in clinical trials. Accessed November 11, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/oxbryta-article-20-procedure-review-started_en.pdf."},{"key":"10.1053\/j.seminhematol.2026.04.001_bib0046","unstructured":"CHMP list of questions to be addressed by the marketing authorisation holder(s) for Oxbryta. Accessed November 11, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/oxbryta-article-20-procedure-chmp-list-questions_en.pdf."},{"key":"10.1053\/j.seminhematol.2026.04.001_bib0047","unstructured":"Committee for medicinal products for human use (CHMP): agenda for the extraordinary meeting. Accessed November 11, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/agenda\/agenda-extraordinary-chmp-meeting-29-july-2024_en.pdf."},{"issue":"7","key":"10.1053\/j.seminhematol.2026.04.001_bib0048","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/14656566.2025.2489123","article-title":"Osivelotor for the treatment of sickle cell disease","volume":"26","author":"Cannas","year":"2025","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.04.001_bib0049","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1021\/acsmedchemlett.5c00076","article-title":"Discovery of osivelotor (GBT021601): a potent, next-generation sickle hemoglobin polymerization inhibitor","volume":"16","author":"Li","year":"2025","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.04.001_bib0050","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/cpt.70028","article-title":"Safety, pharmacokinetics, and pharmacodynamics of osivelotor for Sickle cell disease: first-in-human studies in healthy participants and patients","volume":"119","author":"Lisbon","year":"2026","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.04.001_bib0051","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s42600-022-00224-0","article-title":"Dalcetrapib and reduced glutathione effect on hemoglobin S polymerization studied by NMR","volume":"38","author":"Delgado","year":"2022","journal-title":"Res Biomed Eng"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.04.001_bib0052","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2220769120","article-title":"Control of tissue oxygenation by S-nitrosohemoglobin in human subjects","volume":"120","author":"Reynolds","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"10.1053\/j.seminhematol.2026.04.001_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2024.1394650","article-title":"Modulation of the allosteric and vasoregulatory arms of erythrocytic oxygen transport","volume":"15","author":"Wise","year":"2024","journal-title":"Front Physiol"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.04.001_bib0054","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2019-02-898767","article-title":"Primary polymerization prevention","volume":"133","author":"Steinberg","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.04.001_bib0055","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood.2025029447","article-title":"Epigenetic drug remedies for SCD root cause pathophysiology","volume":"146","author":"Saunthararajah","year":"2025","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.04.001_bib0056","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.2023020345","article-title":"Help on the way to unsilence HbF","volume":"141","author":"Dean","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.04.001_bib0057","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood.V96.7.2379","article-title":"2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia","volume":"96","author":"Koshy","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.04.001_bib0058","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood.V99.11.3905","article-title":"Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia","volume":"99","author":"DeSimone","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.04.001_bib0059","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2003-05-1738","article-title":"Effects of 5-aza-2\u2032-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.04.001_bib0060","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1182\/blood-2022-169283","article-title":"ASCENT1: a phase 2 trial to evaluate the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with Sickle Cell disease","volume":"140","author":"Andemariam","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.04.001_bib0061","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood-2020-141145","article-title":"In vitro characterization of FTX6058, a novel small molecule fetal hemoglobin inducer for sickle cell disease","volume":"136","author":"Stuart","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.04.001_bib0062","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2021-151426","article-title":"Ftx-6058 induces fetal hemoglobin production and ameliorates disease pathology in sickle cell mice","volume":"138","author":"Matson","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.04.001_bib0063","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/blood-2025-1157","article-title":"Pociredir, a novel oral once-daily fetal hemoglobin inducer: results from the Phase 1b pioneer study in adult participants with severe sickle cell disease and hydroxyurea intolerance or unresponsiveness","volume":"146","author":"Alan","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.04.001_bib0064","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood.2024028006","article-title":"Novel, potent, and orally bioavailable LSD1 inhibitors induce fetal hemoglobin synthesis in a sickle cell disease mouse model","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.04.001_bib0065","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1073\/pnas.71.12.4864","article-title":"Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease*","volume":"71","author":"Hofrichter","year":"1974","journal-title":"Proc Natl Acad Sci"},{"issue":"7823","key":"10.1053\/j.seminhematol.2026.04.001_bib0066","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(73)93163-2","article-title":"Iron-deficiency anemia and sickle-cell disease: a hypothesis","volume":"2","author":"Lincoln","year":"1973","journal-title":"Lancet (Lond, Engl)"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.04.001_bib0067","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJM198303033080918","article-title":"Improved survival of iron-deficient patients with sickle erythrocytes","volume":"308","author":"Castro","year":"1983","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.04.001_bib0068","doi-asserted-by":"crossref","DOI":"10.1182\/hem.V19.5.202256","article-title":"Iron-restricted erythropoiesis in Sickle Cell disease","volume":"19","author":"Rees","year":"2022","journal-title":"Hematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.04.001_bib0069","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1182\/blood.2022017209","article-title":"Isn\u2019t it ironic: better RBCs by blocking iron","volume":"140","author":"Parrow","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.04.001_bib0070","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/ajh.27267","article-title":"Iron restriction in sickle cell disease: when less is more","volume":"99","author":"Castro","year":"2024","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.04.001_bib0071","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/blood.2021014716","article-title":"The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease","volume":"140","author":"Nyffenegger","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.04.001_bib0072","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood-2024-204708","article-title":"Pharmacological inhibition of TMPRSS6 decreases hemoglobin concentration and red blood cell (RBC) hemolysis in a mouse model of sickle cell disease","volume":"144","author":"Giannini","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.04.001_bib0073","article-title":"Phase 1 healthy volunteer study of DISC-3405, a recombinant humanized antibody targeting TMPRSS6","volume":"144","author":"Liu","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.04.001_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.brci.2025.100010","article-title":"Restricting glycine uptake with bitopertin improves erythropoiesis in preclinical models of Diamond-Blackfan anemia","volume":"1","author":"Doty","year":"2025","journal-title":"Blood Red Cells Iron"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.04.001_bib0075","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.2022016218","article-title":"Dietary iron restriction protects against vaso-occlusion and organ damage in murine sickle cell disease","volume":"141","author":"Li","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.04.001_bib0076","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.70262","article-title":"Iron deficiency is associated with reduced levels of inflammation and haemolysis in patients with HbSS and HbSC and reduced clinical admissions in those with HbSC","volume":"208","author":"Villaboni","year":"2025","journal-title":"Br J Haematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:10:01Z","timestamp":1785330601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0037196326000260"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.04.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"More disease-modifying therapies for sickle cell disease: Are small molecules and drug repurposing the way forward?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}